Scynexis Inc (SCYX): Total Assets
$59.03M
As of 2025-12-31
$74.97M
As of 2026-06-30
-12.4%
3-year compound annual growth
-10.5%
5-year compound annual growth
+1.8%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $59.03M | -34.9% | 2026-03-04, Balance as of period end |
| 2024-12-31 | $90.64M | -29.4% | 2026-03-04, Balance as of period end |
| 2023-12-31 | $128.41M | +46.2% | 2025-03-12, Balance as of period end |
| 2022-12-31 | $87.81M | -26.7% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $119.84M | +16.9% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $102.54M | +79.4% | 2022-03-29, Balance as of period end |
| 2019-12-31 | $57.15M | +7.5% | 2021-03-29, Balance as of period end |
| 2018-12-31 | $53.17M | +16.0% | 2020-03-11, Balance as of period end |
| 2017-12-31 | $45.85M | -23.3% | 2019-03-14, Balance as of period end |
| 2016-12-31 | $59.79M | +21.3% | 2018-03-13, Balance as of period end |
| 2015-12-31 | $49.27M | +24.2% | 2017-03-13, Balance as of period end |
| 2014-12-31 | $39.67M | +220.3% | 2016-03-07, Balance as of period end |
| 2013-12-31 | $12.39M | n/a | 2015-03-30, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Scynexis Inc (SCYX) | 2025-12-31 | $59.03M | -34.9% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $25.65M | -52.2% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $20.27M | -14.8% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $29.92M | -16.5% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $769.28M | -11.0% |
| Alumis Inc. (ALMS) | 2025-12-31 | $411.94M | +20.8% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $377.38M | -28.3% |
| uniQure N.V. (QURE) | 2025-12-31 | $824.91M | +48.2% |
| Celularity Inc (CELU) | 2025-12-31 | $107.33M | -19.1% |
Compare SCYX, CASIF, EVFM, SLGL side by side · Screen every company in Pharmaceutical Preparations ↗